Raymond James Financial Inc. Acquires Shares of 161,708 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Raymond James Financial Inc. purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 161,708 shares of the medical instruments supplier's stock, valued at approximately $14,900,000. Raymond James Financial Inc. owned about 0.72% of LeMaitre Vascular as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Victory Capital Management Inc. increased its stake in shares of LeMaitre Vascular by 3.2% during the 4th quarter. Victory Capital Management Inc. now owns 54,738 shares of the medical instruments supplier's stock worth $5,044,000 after purchasing an additional 1,678 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of LeMaitre Vascular by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier's stock worth $18,037,000 after purchasing an additional 4,241 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of LeMaitre Vascular by 2.8% during the 4th quarter. Jones Financial Companies Lllp now owns 6,987 shares of the medical instruments supplier's stock worth $644,000 after purchasing an additional 187 shares during the last quarter. Norden Group LLC increased its stake in shares of LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock worth $218,000 after purchasing an additional 103 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 293 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Remove Ads

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.79% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

LMAT has been the topic of a number of research analyst reports. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital raised their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $2.19 during midday trading on Friday, reaching $83.49. 1,117,137 shares of the company's stock were exchanged, compared to its average volume of 147,982. The company's 50 day simple moving average is $94.32 and its two-hundred day simple moving average is $94.43. The firm has a market capitalization of $1.88 billion, a PE ratio of 45.62, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be issued a dividend of $0.20 per share. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Thursday, March 13th. LeMaitre Vascular's dividend payout ratio (DPR) is currently 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.